A BIRMINGHAM company creating new treatments for life-threatening and drug-resistant bacterial infections has received a cash injection from Midven’s Early Advantage Fund.

Abgentis, based at the Birmingham Research Park at the University of Birmingham in Edgbaston, will receive £75,000 from the fund in up to three milestone-driven tranches to establish proof of concept.

The company is working to modify the antibiotic compound novobiocin, originally used to treat infections in the 1960s but which was repl......for the full story register now for free or login below...